Pfizer Research and Quality Improvement Grant Request for Proposals
Pfizer funds research and quality improvement projects to enhance care for elderly and complex HR+/HER2- metastatic breast cancer patients in Italy, focusing on real-world, patient-centered innovations.
Funder: Pfizer Inc.
Due Dates: March 27, 2026 (Full application) | November 15, 2026 (Documentation for selected projects)
Funding Amounts: Up to EUR 50,000 per project; total program budget EUR 150,000; max project length 1 year
Summary: Supports research and quality improvement projects to enhance care for HR+/HER2- metastatic breast cancer patients in Italy, focusing on elderly and complex cases using real-world, patient-centered strategies.
Key Information: Applicants must be based in Italy; only organizations are eligible, not individuals.
Description
This grant program from Pfizer supports research and quality improvement (QI) initiatives aimed at improving the quality of care for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) in Italy who are receiving first-line cyclin-dependent kinase (CDK4/6) inhibitors. The focus is on vulnerable populations, particularly patients aged 65 and older, those with comorbidities, polypharmacy, frailty, or specific tumor characteristics.
Projects should propose innovative, scalable, and patient-centered approaches that can be integrated into clinical practice. Areas of interest include digital tools for patient monitoring, multidisciplinary care models, quality of life improvement, optimization for elderly and frail patients, patient and caregiver engagement, and digital health solutions. Both QI and research proposals are welcome, provided they demonstrate measurable improvements in patient outcomes and practical applicability in real-world settings.
